回盛生物(300871) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for 2024 is expected to be a loss between RMB 17 million and RMB 23 million, compared to a profit of RMB 16.78 million in the same period last year [4]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss between RMB 14 million and RMB 19 million, compared to a loss of RMB 11.19 million in the same period last year [4]. - The company anticipates a negative impact of approximately RMB 4 million from non-recurring gains and losses on net profit, compared to a positive impact of RMB 27.98 million in the same period last year [7]. Research and Development - The increase in research and development expenses has impacted net profit, with R&D costs rising year-on-year [6]. Sales and Revenue - The sales volume of the chemical drug formulation segment has increased year-on-year, but revenue remained stable due to a decline in product prices affecting gross margin [6].